{"entity":{"id":"nct02711553","kind":"trial","name":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","aka":[],"tldr":"A phase 2 trial of Ramucirumab, Cisplatin, Gemcitabine in metastatic cancer, run by Eli Lilly and Company, active and no longer recruiting.","summary":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer is a phase 2 interventional study registered as NCT02711553 by Eli Lilly and Company, with 309 participants enrolled, started 2016-05-19 and due to reach its primary completion in 2018-02-16. Interventions recorded: Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral. Conditions listed: Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer. Results were posted on ClinicalTrials.gov in 2021; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02711553","url":"https://clinicaltrials.gov/study/NCT02711553"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","monoclonal-antibody","platinum"],"targets":[],"drugs":["ramucirumab","cisplatin","gemcitabine","merestinib"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02711553","phase":"2","setting":"Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer","sponsor":"Eli Lilly and Company","started":"2016-05-19","startedType":"actual","yearReported":2021,"enrolled":309,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival (PFS)","primary":true,"unit":"months","arms":[{"name":"8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine","n":106,"value":6.47,"note":"IQR 3.68 to 8.51; Figures from the ClinicalTrials.gov results section (first posted 2021-02-26), not from a publication"},{"name":"80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine","n":102,"value":6.97,"note":"IQR 4.34 to 9.79"},{"name":"Pooled Placebo","n":101,"value":6.64,"note":"IQR 4.11 to 9.72"}],"source":"https://clinicaltrials.gov/study/NCT02711553?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine","n":106,"value":10.45,"note":"IQR 8.48 to 11.76; Figures from the ClinicalTrials.gov results section (first posted 2021-02-26), not from a publication"},{"name":"80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine","n":102,"value":14.03,"note":"IQR 11.96 to 16.36"},{"name":"Pooled Placebo","n":101,"value":13.04,"note":"IQR 11.40 to 15.31"}],"source":"https://clinicaltrials.gov/study/NCT02711553?tab=results"},{"endpoint":"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)","unit":"%","arms":[{"name":"8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine","n":106,"value":31.1,"note":"95% CI 22.3 to 39.9; Figures from the ClinicalTrials.gov results section (first posted 2021-02-26), not from a publication"},{"name":"80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine","n":102,"value":19.6,"note":"95% CI 11.9 to 27.3"},{"name":"Pooled Placebo","n":101,"value":32.7,"note":"95% CI 23.5 to 41.8"}],"source":"https://clinicaltrials.gov/study/NCT02711553?tab=results"}]},"route":"/trials/nct02711553/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"merestinib","kind":"drug","name":"Merestinib","route":"/drugs/merestinib/"},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}